Back

SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

28 August 2023 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardiotoxicity: mechanisms, biomarkers, and treatment Cardio-Oncology ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

7 More presentations in this session

Presentation thumbnail
The potentially protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients
Doctor S. Maragkoudakis (Chania, GR)
Abstract Slides Video
Presentation thumbnail
SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
The use of high sensitivity troponin T as a biomarker of anthracycline cardiotoxicity
Doctor C. Bannister (London, GB)
Abstract Slides Video
Presentation thumbnail
The utility of the HFA-ICOS cardiotoxicity risk assessment tool for HER2-targeted cancer therapies in patients with metastatic breast cancer: from theory to clinical practice.
Doctor D. Leocachin Parra (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Differences in the prevalence of cardiovascular toxicity in a cohort of female breast cancer patients according to the different cardiotoxicity definitions
Doctor J. Herrera (Cordoba, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiotoxicity: mechanisms, biomarkers, and treatment

The Event

Event poster

ESC Congress 2023

28 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Presentation
MyD-88/NLRP-3 inhibition by dapagliflozin protects against anthracycline and trastuzumab cardiotoxicity in preclinical models
thumbnail
Congress Presentation
Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3
thumbnail
Congress Presentation
GLP1-RA associated with PCSK9i as new therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources